While most of the pharmaceutical industry screens against already described molecular “targets” to find potential drug candidates, Amylin has taken an integrated biological approach. Its discovery process is designed to identify previously unknown peptide hormones—molecular chains of amino acids that circulate through the blood stream and play important metabolic roles. Amylin scientists are discovering novel peptide hormones, uncovering their therapeutic potential, improving their performance, and creating innovative new therapies designed to address unmet medical needs.

A key resource developed over time is a proprietary and continually growing polypeptide hormone library that encompasses an extensive panel of more than 1,000 potentially valuable biologics taken from nature. These have been synthesized to create a rich source of compounds for ongoing research into functionality, utility, and potential value in the treatment of human disease.

In addition to internal development programs, Amylin is also applying its deep understanding of metabolic medicine and the role of peptide hormones in collaborations with highly specialized research organizations. These R&D efforts, focused on very long-term opportunities, are exploring the potential role of biologically active peptides in psychiatric, inflammatory, and other disorders.